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4. The equipment at the McMaster site (lines 216, 228) needs to be specified. 5 . Line 242-243: Please clarify: "screening and collection of baseline assessments of primary and secondary outcomes will be performed by a statistician" Why would assessments be carried out by a statistician? 6. Blood samples: Would not a central lab be more appropriate to enhance consistency? 7. There is no mention of an intention-to-treat analysis; in lines 185-186 it is stated: Participants unable to comply with the adherence criterion will be asked to withdraw from the trial. Will these participants be replaced? Will they be included in the analysis?
Other points for clarification: In line 121 it is stated that BWSTT is a passive exercise, However, Please clarify "application of passing" on line 234.
Will the site of pain be recorded as well as the intensity? That would be useful with respect to possible overuse injuries Is there a common case report form for the trial? Can all sites upload data into the database, or will this be done manually at the Vancouver site?
REVIEWER
Peter H. Gorman, MD University of Maryland School of Medicine, Baltimore, MD, United States REVIEW RETURNED 07-May-2018
GENERAL COMMENTS REVIEW OF THE PROTOCOL: Effects of exercise interventions on cardiovascular health in individuals with chronic, motor-complete spinal cord injury: Protocol for a randomized controlled trial.
This protocol details a prospective three center randomized clinical trial to determine the effects of two different exercise interventions on arterial stiffness in individuals with chronic motor complete spinal injury at the T6 level or higher. Additionally, multiple secondary outcomes will be measured, including (1) cardiovascular parameters, (2) autonomic function, (3) body composition, (4) blood hematological and metabolic profiles, (5) cardiorespiratory fitness, and (6) quality of life and physical activity outcomes.
The authors are employing the measurement of carotid to femoral pulse wave velocity (cfPWV) as a surrogate for arterial stiffness. Their underlying reason for using this marker as the primary outcome measure rests on fairly extensive prior work in other disease states and some prior work in spinal cord injury. An increase in cfPWV has been correlated with an increased risk of secondary cardiovascular risk in patients with hypertension, and end stage renal disease, and has also been shown to cause other secondary conditions such as left ventricular hypertrophy which in turn can lead to stroke and heart attack. [1] The authors reference preliminary work that has shown that cfPWV changes rapidly after acute spinal cord injury. [2] They also reference work showing that cfPWV is elevated in men with SCI compared to matched controls. [3] The problem however with potentially using this as the primary outcome measure of cardiovascular risk is that in this sympathetically impaired population, how is one to differentiate the changes in cfPWV caused by vasoactive and immobility phenomenon (as is likely to be the case acutely after SCI) from changes in stiffness due to atherosclerotic vascular disease? I am not aware of any longitudinal study of cfPWV in chronic SCI subjects that would define the normal variability in this measure. To their credit however, Dr. Krassioukov and colleagues have done a robust testretest reliability study [4] and have also compared SCI athletes with sedentary SCI individuals, demonstrating a diminished cfPWV in the athletes. [5] So yes, cfPVW can be a reasonable outcome measure. But if one is looking to improve cardiovascular fitness, shouldn't the peak VO2 measurements take a larger role?
The proposed randomization in this study is to either arm cycle ergometry training (ACET) or body weight supported treadmill training (BWSTT). There is no non-interventional control group. The authors don't explain the lack of this type of control. This would be reasonable if a prior randomized clinical trial had occurred with a non-interventional control (or a delayed entry crossover control), but I am not aware of such a study. The BWSTT will not be an aerobic challenge since these will be AIS A and B subjects. Rather, BWSTT represents a postural challenge and possibly a passive range of motion challenge against spastic limbs. I don't understand why this challenge would potentially change cfPVW more than ACET. Work by Kressler, et al.
[6] has suggested that robotically assisted weight supported treadmill training (RAWSTT) done passively does not produce a metabolic effect. Work at my center has shown that RAWSTT with coaching can produce an aerobic response, but that was with motor incomplete individuals.
[7] Bottom line question is -why BWSTT as the major intervention in this study? An alternative design might have employed lower extremity functional electrical stimulation instead of BWSTT in order to provide more of a cardiovascular (aerobic) challenge. That being said, there is a need to explain the lack of a standard care control (or the possibility of introducing this as a third arm, possibly with crossover to intervention for equipoise). 
VERSION 1 -AUTHOR RESPONSE
Reviewer: 1
Future tense should be used throughout; often past tense is used, e.g lines 232, 338. There are some typing errors, e.g. line 6, "factors"; line 233 "sheer"
The necessary corrections have been made to lines 232 and 338 (changed to future tense). Typographical errors on line 6 and 233 have also been corrected.
When did recruitment commence and has it been completed? Does ethics approval cover all sites?
Important trial status information has now been added to the manuscript under a "Trial status" subheading (line 470). Ethical approval was obtained for each site, please see approval numbers under the "Ethics approval" subheading (line 475).
This protocol meets some of the quality requirements for randomised controlled trials, e.g. the eligibility requirements are clearly specified, randomisation via a central web-based randomisation service, with the sequence generated independent of trial, concealed allocation. However, other elements have not been clearly articulated, e.g.
The outcome assessors were not blinded to trial allocation as they were involved in the training of participants, this has already been addressed in the 'strengths and limitations' section of the manuscript (line 48). This has now also been emphasised in the 'Assessments' section of the manuscript.
2. What is the time point for the primary outcome measure, 3 or 6 months?
The primary outcome measure will be assessed at both 3 and 6 months as outlined in the statistical analysis section (line 410) and Table 3 . The above comment helped to identify a typo in the statistical analysis section, as the secondary outcome measures are parameterized as a 2 rather than 3-level factor (only measured at baseline and 6 months). This has now been specified in the manuscript (line 415). For clarity, we have also emphasised the time points for data collection under the 'Assessments subheading'.
3. The protocols for the intervention and progression of intensity have been clearly described. Although reliability of assessments at the Vancouver laboratory had been established, what steps were taken to ensure fidelity of assessments at all sites? (See Abstract, last dot point)
We took significant consideration while planning the trial in order to achieve consistency with the interventions and outcome measure evaluations:
-Firstly, PI's and personnel from all sites that were involved in the trial had an initial face-to-face meeting and performed standardised training at the McMaster study site regarding all aspects of the trial. -We also developed detailed and common standardised operating procedures (SOPs) for each of the training modalities and collection of various outcome measures to ensure reproducibility across sites. -Finally, during the period of the trial we had regular 6-month video conferences to act as refreshers for the most critical aspects of data collection. -Furthermore, an executive committee, including principal investigators (A.V.K, M.M and B.C.C) and assessors from all sites, convenes on a regular basis to discuss any ongoing data collection issues. The principal investigators at each site are responsible for ensuring the fidelity of assessments.
This information has now been explained in the manuscript under the 'Assessments' subheading. In light of this, the limitations bullet point after the abstract has been amended accordingly.
4. The equipment at the McMaster site (lines 216, 228) needs to be specified.
Thank you for pointing this out. The information of the equipment at McMaster site have been added to the manuscript (line 212 and 223).
5. Line 242-243: Please clarify: "screening and collection of baseline assessments of primary and secondary outcomes will be performed by a statistician" Why would assessments be carried out by a statistician?
Thank you for mentioning this point, which was a typographical error. The manuscript has been amended accordingly.
6. Blood samples: Would not a central lab be more appropriate to enhance consistency?
The reviewer raises a good point. However, logistically (and financially) this would be incredibly difficult to co-ordinate across the breadth of Canada. We selected specific, certified, clinical laboratories at each site whose staff are highly trained and equipment is regularly serviced and maintained. Prior to initiation of the trial, we looked at normative population values from each laboratory to compare the consistency across parameters. Ultimately we are interested in the changes overtime in response to each exercise intervention. Given pre-post samples are analysed within the same laboratory this ensures a necessary degree of consistency. Moreover, we anticipate that any clinically meaningful changes in blood biomarkers will be of a greater magnitude than any day-to-day inter-assay variability.
7. There is no mention of an intention-to-treat analysis; in lines 185-186 it is stated: Participants unable to comply with the adherence criterion will be asked to withdraw from the trial. Will these participants be replaced? Will they be included in the analysis?
Thank you for requesting further clarification regarding our statistical analysis. Withdrawn participants will not be replaced and an intention-to-treat will be utilised. We have now added a statement into the manuscript (line 431).
Other points for clarification:
In line 121 it is stated that BWSTT is a passive exercise, However, We stand by our current viewpoint that BWSTT is a passive exercise. While Forrest et al, 2007 demonstrated some degree of neuromuscular plasticity with repetitive locomotor training (over 97 sessions), the stepping movement was still initiated and guided by trainers. Moreover, they did not observe any clinical changes in the total motor score obtained by the International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) evaluation (pre 16/100 vs. post 17/100) or level (which remained at C6). A single-case report is also one of the lowest levels of evidence. Functionally, the authors noticed an improvement in standing tolerance when using a standing frame, although this is likely due to improvements in upper-body strength rather than lower extremity neuromuscular changes. Decisively, Forest et al, (2007) themselves state in their paper that trainers help participants to "passively" step on the treadmill.
Please clarify "application of passing" on line 234.
This has been corrected in the manuscript.
Will the site of pain be recorded as well as the intensity? That would be useful with respect to possible overuse injuries
As a quality of life outcome measure pain is assessed via subscales from the SF-36 (capturing intensity during the past 4 weeks and the level of interference with normal life) and an 11-point visual analogue scale (intensity). However, adverse events (AE) are recorded for each training session, with pain intensity and location recorded. An adverse event log is kept, which captures these occurrences. The project site PI's (A.K, M.M, and B.C.C) reviews each AE and judges if it is mild, moderate or severe. These cases are then reported to a Data and Safety Monitoring Committee. This additional information is now reported in the manuscript under the 'safety' subheading.
Is there a common case report form for the trial? Can all sites upload data into the database, or will this be done manually at the Vancouver site?
Yes, there are common data collection forms for the trial. These are uploaded electronically onto an internet database (Empower), already mentioned on line 163 (where a url is provided) and line 401). This should provide a brief response to the following questions:
-How was the development of the research question and outcome measures informed by patients' priorities, experience, and preferences? -How did you involve patients in the design of this study? -Were patients involved in the recruitment to and conduct of the study? -How will the results be disseminated to study participants? -For randomised controlled trials, was the burden of the intervention assessed by patients themselves? -Patient advisers should also be thanked in the contributorship statement/acknowledgements.
If patients and or public were not involved please state this.
The primary research questions and outcome measures of the trial were inspired by careful evaluation of research evidence, taking into consideration the priorities for health and recovery identified by individuals with SCI from original research (Anderson, 2004. J Neurotrauma) or during personal clinical/research interactions of the lead PI (A.V.K) with individuals with SCI. This study protocol addresses these priorities. We already note in the paper that the experience of the wider study team was used to develop the protocols. The protocols reflect their years of experience working with this population and understanding of what is tolerable or possible for people with SCI. Although no formal review of the protocol was performed by people with SCI, informal conversations and feedback from exercisers with SCI was taken into consideration. A number of the study team were and still are actively engaged with the wider SCI community and pertinent information was incorporated into the study protocol.
We also have additional strategies to ensure study results are widely disseminated. A summary of the study's findings will be posted on the international collaboration of repair discoveries (ICORD) website and published in the magazines of service organisations for people with SCI in the provinces where participants were recruited (i.e. the SCI BC and SCI ON magazine publications). Furthermore, participants will receive detailed individualized feedback. These points have now been emphasised in the manuscript.
REVIEW OF THE PROTOCOL: Effects of exercise interventions on cardiovascular health in individuals with chronic, motor-complete spinal cord injury: Protocol for a randomized controlled trial.
The authors are employing the measurement of carotid to femoral pulse wave velocity (cfPWV) as a surrogate for arterial stiffness. Their underlying reason for using this marker as the primary outcome measure rests on fairly extensive prior work in other disease states and some prior work in spinal cord injury. An increase in cfPWV has been correlated with an increased risk of secondary cardiovascular risk in patients with hypertension, and end stage renal disease, and has also been shown to cause other secondary conditions such as left ventricular hypertrophy which in turn can lead to stroke and heart attack. [1] The authors reference preliminary work that has shown that cfPWV changes rapidly after acute spinal cord injury. [2] We would like to point out that this study referenced by the reviewer did not measure cfPWV. This preliminary work provides evidence for vascular remodeling acutely following SCI, however, assessments of diameter, blood flow and shear rate were measured with echo Doppler ultrasound. Moreover, flowmediated dilation (FMD) was used to measure endothelial function in the superficial femoral artery (SFA).
They also reference work showing that cfPWV is elevated in men with SCI compared to matched controls. [3] The problem however with potentially using this as the primary outcome measure of cardiovascular risk is that in this sympathetically impaired population, how is one to differentiate the changes in cfPWV caused by vasoactive and immobility phenomenon (as is likely to be the case acutely after SCI) from changes in stiffness due to atherosclerotic vascular disease?
Thank you for raising this point. You are correct that sympathetic tone is important to consider. However, we contend that this is more important when measuring the peripheral vasculature, which we do not intend to do in this current study. The measure of cfPWV specifically is a measure of central conduit artery stiffness, not peripheral muscular artery stiffness. While sympathetic tone might play a role, conduit artery stiffness is more likely a result of structural changes in collagen and elastin deposition in the artery itself (representative of atherosclerotic vascular disease), rather than changes in the sympathetic tone of the artery. Moreover, you point out an immobility phenomenon, which is likely to be present 'acutely' after SCI. However, participants recruited into this study have chronic (> 1 year) SCI and are not immobilized.
I am not aware of any longitudinal study of cfPWV in chronic SCI subjects that would define the normal variability in this measure.
You are correct with this observation -there is no longitudinal study of this measure in SCI to define normal cfPWV variability. This is an evolving area, with most of the work published on this outcome measure being performed over the past decade by our team-grant "group" (including Toronto Research Institute). That being said, Dr. Craven's group found no relationship between time post injury (TPI and cfPWV, which would suggest those individuals that are injured longer do not experience increased arterial stiffening (Miyatani et al, 2017 , E J of Prev Cardiol. Moreover, another study performed by this research group reported the test-retest (day-to-day) reliability of cfPWV [Miyatani et al, 2012 , J Spinal Cord Med, 35 (5)]. The authors demonstrated that changes in cfPWV above 104 cm/second with repeated testing likely represents true changes in health status. This supporting reference has now been added into the manuscript (line 131) to support the use of 1 m/s.
To their credit however, Dr. Krassioukov and colleagues have done a robust test-retest reliability study [4] and have also compared SCI athletes with sedentary SCI individuals, demonstrating a diminished cfPWV in the athletes. [5] So yes, cfPVW can be a reasonable outcome measure. But if one is looking to improve cardiovascular fitness, shouldn't the peak VO2 measurements take a larger role?
The reviewer has raised some interesting points and we would like to thank him for this comment. While the pathophysiology of arterial stiffening in the SCI community is unknown, it may be related to a variety of factors including inactivity following paralysis, injury related changes in sympathetic innervation and the resultant BP lability, or atherosclerotic vascular disease. We would agree that a longitudinal study tracking these outcomes and vascular health is necessary next step to better understand the mechanisms of arterial stiffening post-SCI. Our decision to select cfPWV as the primary outcome measure was based on the evidence that (1) cfPWV is elevated in those with SCI compared to their able-bodied peers, (2) cfPWV is lower in those with SCI who are habitually active compared to their sedentary SCI peers, (3) the measure of cfPWV itself is a risk factor for CVD, which we know is the leading cause of death in the SCI community, and (4) that our lab and Toronto have demonstrated it is a reliable measure. We would also like to add that while low CRF is an important risk factor for all-cause and CVD mortality in able-bodied individuals (Sui et al 2007. JAMA), there are no prospective cohort studies assessing the link between CRF and mortality in persons with SCI specifically. Moreover, associations between upper-body VO2peak and CVD risk factors in this population are not as consistent as those observed in the able-bodied literature. Consequently, while VO2peak measurements are important and likely provide information on functional capacity (this has implications for performing activities of daily living and independence) we do not feel it is justifiable to replace our primary outcome measure cfPWV with VO2 peak. In general, we are looking for improving the health globally not just aerobic capacity.
[6] has suggested that robotically assisted weight supported treadmill training (RAWSTT) done passively does not produce a metabolic effect. Work at my center has shown that RAWSTT with coaching can produce an aerobic response, but that was with motor-incomplete individuals.
[7] Bottom line question is -why BWSTT as the major intervention in this study? An alternative design might have employed lower extremity functional electrical stimulation instead of BWSTT in order to provide more of a cardiovascular (aerobic) challenge. That being said, there is a need to explain the lack of a standard care control (or the possibility of introducing this as a third arm, possibly with crossover to intervention for equipoise).
This is an interesting comment from the reviewer. Other studies in the SCI population have compared certain exercise modalities without including a control group or justifying their decision not too (Kressler et al, 2013; Bakkum et al, 2015. J Rehabil Med). While we agree that perhaps a delayed entry crossover study would be a viable alternative, this would extend the duration of the trial by 6 months and may raise an ethical consideration by delaying the participants' enrollment in an exercise intervention, aimed at improving health. Moreover, it is important to note that interpreting data from RCT's with a 'true' lifestyle control group can actually be compounded by this group becoming worse over time (Hicks et al, 2003. Spinal Cord) . Considering this, we feel we are justified in using our current approach to compare the effectiveness of two commonly performed exercise modalities rather than comparing to a noninterventional control group.
While we agree that passive treadmill exercise does not produce a metabolic effect, particularly in motorcomplete SCI, we draw on pre-clinical work ( We agree, 60 minutes per session is a considerable amount of time for BWSTT. Given the trial has been ongoing since 2013 we have successfully managed to implement this through having a large study team and group of volunteers, whom have all received extensive training prior to working with participants.
I applaud the investigators technique for making up for missed sessions in a specific predetermined way. I would like to suggest a minor clarification that the 24-hour blood pressure monitoring is really only 15 hours since it doesn't include 9pm to 6am.
Thank you for drawing our attention to this. This was a typographical error, we do indeed measure BP for 24-hours. The manuscript has been amended accordingly (line 299).
Although it is indicated in table 3, the frequency of performing the International autonomic standards evaluation is not mentioned in the text.
We would like to acknowledge this point and draw your attention to the other reviewers comment (clarity of how often the primary outcome measure is assessed). In the 'Assessments' and 'statistical analysis' section we have outlined how frequently the primary and secondary outcome measures are assessed. This information is also displayed in Table 3 .
The specifics of the peak VO2 testing (e.g. sampling of VO2 over how many seconds and repeated how many times) should be clarified. The total estimated burden of testing should be estimated.
We appreciate this valuable point raised by the reviewer. Many manuscripts are not descriptive enough with how they have collected and analysed VO2 peak data. With regards to the exercise testing itself, assessors will take every attempt to keep motivation consistent between trials and ensure the participant reaches the maximal effort (i.e. RPE >17). We anticipate the test duration will range between 6 to 15 min (Eerden et al, 2017. Disability and Rehabilitation) as this will yield a fatigue-limited testing. Breath-by-breath data will be averaged over the period of 20 seconds and the highest value will be recorded as VO2 peak. The manuscript has been amended to clarify the above comment (line 355).
Given the challenges of achieving reliable peak values that we might encounter in this population (≥T6 SCI) and the likelihood of peripheral fatigue, we intend to add a submaximal exercise capacity parameter (i.e. oxygen uptake at ventilatory threshold), which will be identified visually using different methods ( With regard to the possible effects of sympathetic tone changes in these patients and that effect on cfPWV, the authors make the argument in their response to reviewer 3 that since this measurement occurs between carotid and femoral arteries, and sympathetic tone affects more distal arterial tone, that the cfPWV will reflect changes in collagen and elastin deposition, and not sympathetic tone per se. This argument that sympathetic tone is not a major player in cfPWV results is reasonable, but I would suggest that the authors include this argument somewhere in the manuscript, as I would think that SCI clinicians reading this work would still wonder about the possibility.
The authors have added a reference pointing out that changes greater than 1 m/s in cfPWV would be clinically relevant. They have also put forward the argument that cfPWV is the best overall outcome measure (as opposed to peak VO2) to explore global cardiovascular fitness. They have also justified why they have chosen in their inclusion criteria that cfPWV values have to be greater than that of age matched able-bodied individuals.
Finally, the authors have also made other specific changes that have corrected typographical errors and omissions.
VERSION 2 -AUTHOR RESPONSE

Reviewer 2
The strengths and limitations section has been refined. Trial status and ethical issues have been updated. The fact that the outcome assessors were not blinded and the timeline for the primary and secondary outcome measures have been clarified. The use of an intention to treat analysis has been stated. It is appreciated that the authors have further discussed their assertion that BWSTT is a passive exercise. For motor complete individuals I believe that this is a reasonable assertion since the inclusion criteria for the study enrolls only AIS A and B individuals. The authors have addressed the issue of Patient and Public Involvement.
Thank you. No further response required.
With regard to the possible effects of sympathetic tone changes in these patients and that effect on cfPWV, the authors make the argument in their response to reviewer 3 that since this measurement occurs between carotid and femoral arteries, and sympathetic tone affects more distal arterial tone, that the cfPWV will reflect changes in collagen and elastin deposition, and not sympathetic tone per se. This argument that sympathetic tone is not a major player in cfPWV results is reasonable, but I would suggest that the authors include this argument somewhere in the manuscript, as I would think that SCI clinicians reading this work would still wonder about the possibility.
Thank you for emphasizing the need to include this argument in the manuscript to provide further clarity for the reader. We have made the following change to the manuscript: 'Sympathetic tone changes in individuals with high-level SCI are important to consider when measuring the peripheral vasculature. However, the measure of cfPWV is specifically a measure of central conduit artery stiffness, not peripheral muscular artery stiffness. Therefore, we contend that conduit artery stiffness is more likely a result of structural changes in collagen and elastin deposition in the artery itself (thus representative of atherosclerotic vascular disease), rather than changes in the sympathetic tone of the artery per se'. (Pg. 5. Line 79).
Thank you. No author action necessary.
We have conducted a final sweep of the manuscript and addressed any remaining typographical errors/omissions and provided further clarity where we feel this is necessary:
